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The cDNA encoding omithine aminotransferase (EC 2.6.1.13; OAT) was isolated from a human kidney cDNA library. 
The isolated cDNA contained the entire protein coding region and partial 3’- and S-~transla~ regions. The nucleotide 
sequences of human kidney OAT cDNA were absolutely homologous with t ose of human liver OAT cDNA, and human 
kidney and liver OAT fused completely against he antibody to human kidney OAT in an Ouchterlony double diffusion 
test. These findings settled the controversy as to which characteristics of liver and kidney OAT isozymes are different. 
An N-terminal sequence analysis of purified mature human kidney OAT clarified that the leader peptide was cleaved 
between Gln-35 and Gly-36. 
Omithine aminotransferase; cDNA; Nucleotide sequence; Pyridoxal phosphate binding site; Isozyme; (Human liver, Human kidney) 
1. INTRODUCTION 
Ornithine aminotransferase (OAT) (L- 
ornithine : 2-oxo-acid aminotransferase, EC 
2.6.1.13) is a mitochondri~ matrix enzyme which 
catalyzes a reversible reaction of interconversion 
between or~thine and glutamic ~-semi~dehyde 
(cyclized form, A’-pyrroline-5-carboxylate), and 
the latter product can be reversibly converted to 
glutamate or proline. This enzyme is existent in 
many tissues, including liver, kidney, small in- 
testine, brain and eye. Of these, liver and kidney 
OAT differ significantly in their regulation by 
various hormonal and nutrition~ factors. In order 
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The nucleotide sequence presented here has been submitted to 
the EMBL/GenBank database under the accession o. YO7511 
to account for this difference, Volpe et al. [I] 
postulated the presence of two organ-specific en- 
zymes, namefy, liver OAT, which is involved in the 
synthesis of ornithine for urea formation, and 
kidney OAT, which participates in ornithine 
degradation to glutamate or proline. The same 
authors [2] also clarified that the two isozymes 
were synthesized at different specific stages of the 
HeLa cell cycle. In addition, Kalita et al. [3] 
reported that rat liver and kidney OATS exhibited 
distinct physicochemical properties which differed 
in heat lability and cysteine contents. On the other 
hand, Sanada et al. [4] and Yip and Collins [5] 
concluded that the two enzymes were not 
distinguishable by chemical or physical methods. 
Recently, the cDNA for OAT mRNA has been 
cloned from human liver [6] and retinoblastoma 
cell lines [7]. However, controversial studies on the 
different characteristics of liver and kidney 
isozymes have not been settled so far [l-5]. 
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Here we report how we independently isolated 
the cDNA for OAT mRNA from a human kidney 
cDNA library and determined nucleotide se- 
quences in an attempt to settle this historical con- 
troversy. 
2. MATERIALS AND METHODS 
2.1. Preparation of rat liver OAT cDNA 
The rat OAT cDNA was isolated from a rat liver cDNA 
library constructed in plasmid pBR322, using a 33mer 
oligonucleotide probe, involving the rat liver OAT active site se- 
quences previously reported f8]. A cDNA fragment of about 
250 bp digested with BarnHI and PstI (rIOAT-cDNA 250) was 
used as a probe. 
2.2. Screening of the human kidney OAT cDNA 
A human kidney cDNA library construer in phage XgtlO 
(Clontec Laboratories, Inc., Palo Alto, CA) was screened by 
the procedure of Benton and Davis [9], using rlOAT-cDNA 
250, which was labeled by random oligonucleotide priming [ 101. 
2.3. DNA sequence analysis 
The hkOAT-cDNA clones (see section 3.1) were digested with 
appropriate restriction enzymes and the resulting fragments 
were subcloned into the Ml3 mp18 and mp19 vectors. The 
cDNA inserts were sequenced by the dideoxy chain termination 
method [ll]. 
3. RESULTS AND DISCUSSION 
3.1. Isolation and characterization of human 
kidney OAT cDNA 
Using the rlOAT-cDNA 250 as a probe, eleven 
positive plaques were isolated from 400000 clones 
by screening of a human kidney cDNA library. 
The positive clones were divided into two groups 
containing cDNA inserts of approximately 1.1 and 
1.5 kbp, respectively (hkOAT-cDNAs). A partial 
restriction map of the 1.5 kbp hkOAT-cDNA and 
the DNA sequence strategy are shown in fig.1. 
Fig.2 presents the nucleotide sequence of the 1.5 
and 1 .l kbp hkOAT-cDNAs. The 1.5 kbp 
hkOAT-cDNA contains the entire protein coding 
region of 1317 nucleotides, specifying a protein of 
48 479 Da molecular mass, but lacks the partial 5 ’ - 
and 3’untranslated regions compared with human 
liver OAT cDNA [6]. The 1.1 kbp hkOAT-cDNA 
lacks the entire 5 ‘-untranslated region, but con- 
tains the partial protein coding region and the par- 
tial 3 ’ -untranslated region. Nucleotide sequence 
analysis showed that the nucleotide sequence of the 
5 ’ -untr~slated region, the protein coding region 
5’ 1 c----3 
- 1OObp 
Fig. 1. Partial restriction map and sequence strategy of human 
kidney OAT cDNA. The sequence strategy is summarized 
beneath the map with horizontal arrows indicating the direction 
and extent of each sequence determination. The boxed region 
represents the open reading frame, and the black region shows 
the mitochondrial signal sequence. The thin bars indicate 5’- 
and 3 ‘-untranslated regions. 
and the 3 ‘-untranslated region are absolutely 
homologous with human liver OAT cDNA [6]. 
Furthermore, on an Ouchterlony double diffusion 
plate, the precipitation lines of the specific an- 
tibody IgG for kidney OAT fused completely with 
liver, kidney and brain OAT (fig. 3). These findings 
present critical evidence that liver and kidney en- 
zymes do not constitute one isozyme, thereby sett- 
ling the previously mentioned controversy [l-5]. 
We therefore propose that differenti~ regulation 
of the mRNA level of OAT in kidney and liver 
and, if any, in the cell cycle of HeLa cells may be 
responsible for the 5 ’ -upstream region of the OAT 
gene. Furthermore, elucidation of the regulation 
of ornithine metabolism would be more facilitated 
by investigating the related genes, which are those 
of the enzymes of ornithine synthetic and 
degradative pathways: A’-pyrroline-5-carboxylate 
synthetase, proline dehydrogenase, ornithine car- 
bamoyltransferase, and arginine amidohydrase, 
A ‘-pyrroline-5-carboxylate reductase, 
A’-pyrroline-5-carboxylate dehydrogenase. 
3.2. Mitochondrial signal sequence 
Most nuclear-encoded mitochondrial proteins 
are synthesized as larger precursors with N- 
terminal leader peptides. The sequence of the N- 
terminal 5 residues of the purified mature human 
kidney OAT subunit was determined by a gas 
phase protein sequencer (Model 47OA, Applied 
Biosystems, CA, USA). Our sequence data reveal- 
ed that the leader peptide of human kidney OAT 
was cleaved after Gin-35 to leave an N-terminal 
Gly-36. Furthermore, mature rat liver OAT was 
also processed after Gin-35 (Oyama, R. and 
301 
Volume 255, number 2 FEBS LETTERS September 
5’ Kidney GMTTCCTCAGATCTGTGG~TTCTAC~~GGA~CA 
Liver GMTTCCGCTGT~~TCTGT~TT~CTAC~~~A~CA 
Mrt-Phe-Ser-i.ys-L,eu-Ala-Hl~-Leu-Gln-ArS-Phe-A~a-Val-Leu-Ser-ArS-Gly-Va~-Hl~-Ser-Se~-V~l-A~~-Ser-A~~-Thr-Ser-Val-Ala-Thr 
A'IG TTT TCC AAA CTA CCA CAT TTC CAC ACC ITT GCT GTA CTT ACT CCC CGA GM CAT TCT TCA GTG GCT TCT GCT ACA TCT GTT GCA ACT 
AIG TTT 'ICC AAA CTA tiCA CAT TTC CAU ACG TTT CCT GTA CTT AGT CCC CGA GTT CAT TCT TCA CTG GCT TCT GCT ACA TCT GTT CCA ACT 
1989 
1: 
30 
90 
90 
f 
I.ys-Lyn-Thr-Val-G1niCly-Pro-Pro-Thr-Ser-Asp-Aap-Ile-Phe-Clu-ArS-Clu-Tyr-Lya-Tyr-Gly-Als-Hi~-A~n-Tyr-H~~~P~~-Le"-P~~-V~i 
U.4 AAA ACA GTC CAA;CCC CCT CCA ACC TCT GAT CAC ATT TTT GA.4 AGG GM TAT MG TAT GGT GCA CAC MC TAC CAT CCT TTA CCT GTA 
AU MA ACA CTC CAA GGC CCT CCA ACC TCT CAT GAC ATT TTT CM AGG GM TAT MC TAT GGT GCA CAC MC TAC CAT CCT TTA CCT GTA 
60 
180 
180 
Aia-Leu-GIu-Arg-Gly-Lys-Gly-!le-Tyr-Leu-Trp-Aap-Val-Glu-Gly-ArS-Ly~-Tyr-Phe-A~p-Phe-Leu-Ser-Ser-Tyr-Ser-Al~-V~l-A~n-Gln 90 
CCC C'IG CAG AGA GGA MA GGT ATT TAC TTA TGG CAT GTA GM GGC AGA MA TAT TIT GAC TTC CTG ACT TCT TAC ACT GCT GTC MC CM 27G 
ccc CTG ti~C ACA GGA AM GGT ATT TAC TTA TGG CAT GTA GAA GGC AGA AM TAT TTT GAC TTC CTG ACT TCT TAC ACT GCT GTC MC CAA 270 
Gly-Hfs-Cys-His-Pro-Lys-Ile-Val-Asn-AL-Leu-Lys-Ser-Gln-Val-A~p-Ly~-Leu-Thr-Leu-Thr-S8r-ArS-Al~-Phe-~r-A.n-~n-Val-L~u 120 
tititi CAT TN CAC CCC AAC ATT CTG MT GCT CTC MC ACT CM GTG GAC AAA TTG ACC TTA ACA TCT AGA GCT TTC TAT MT MC GTA CTT 360 
GGti CAT TGT CAC CCC AAG ATT GTG MT GCT CTG MC ACT CM GTG GAC MA TTG ACC TTA ACA TCT AGA GCT TTC TAT MT MC GTA CTl’ 360 
Gly-Glu-Tyr-Glu-Glu-Tyr-Ile~Thr-Lye-Leu-Phe-Aan-Tyr-His-Ly~-V~l-Leu-Pro-Met-~n-Thr-Gly-V~~~~u-A~~-Giy~~u-~?*A~~-Cy8 150 
GGT GAA TAT GAG GAG TAT ATT ACT AAA CTT TTC MC TAC CAC AAA GTT CTT CCT ATG MT At2 GGA GTC GAG GCT Gcb GAG ACT CCC TGT 450 
CCT CAA TAT GAG GAG TAT ATT ACT AAA CTT TTC MC TAC CAC AAA GTT CTT CCT ATG MT ACA GGA GTG GAG GCT ffiA GAG ACT GCC TGT 150 
Lyu-Leu-Ala-ArS-Lys-Trp-Cly-Tyr-Thr-Val-Lye-Gly-fle-Gln-Ly~-Tyr-Lys-Als-Ly~-I1e-V~1-Phs-Al~-Al~-Gly-~n"Phe-Trp-Gly-ArS 180 
AAA CIA GCT CGT AAG TCG GGC TAT ACC GTC MC CCC ATT CAG AAA TAC AM GCA MC ATT GTT Tl-f GCA GCT GGG MC TTC TGG GGT AGG 540 
AM CI'A GCT CW MC TGG GGC TAT ACC GTG MG CCC ATT CAG AM TAC AAA GCA AAG ATT GTT TTT GCA GCT GGG MC TTC TGG GGT AGG 540 
Thr-Leu-Ser-Ala-Iie-Scr-Ser-S~r-Thr-A8p-Pro-~r-S~r-TyK-A~p~ly-Ph~~ly-Pro-P~-~C-Pr~ly-Ph~-~~Il~-Ilr-Pro-Tyr-A~n 210 
ACC TTG TCT GCT ATC TCC ACT TCC ACA GAC CCA ACC AGT TAC CAT GGT l-CT GGA CCA TTT AM: CCC GGA lTC GAC ATC ATT CCC TAT MT 630 
ACC TTC TCT GCT ATC TCC AGT TCC AWL GAC CCA ACC AGT TAC CAT GGT Tl'T GGA CCA 'ITT ATG CCG GGA TTC GAC ATC ATT CCC TAT MT 630 
Asp-Leu-Pro-Ala-Leu-Glu-ArS-Al~-Leu-Gln-A~p-Pra-~n-V~l-Al~-Al~-Ph~-~et-V~l~lu-Pro-Il8~ln-Gly~lu-Al~~ly-V~l-V~l-V~l 240 
CAT CTC CCC GCA CTG GAG CGT CCT CTT CAG CAT CCA MT GTG GCT GCC TTC ATG GTA GM CCA An: CAG GGT GAA GCA GGC GTT GTT GTT 720 
CAT CTC CCC GCA CTC GAG CGT GCT CTT CAG CAT WA MT GTG GCT GCG lTC ATG GTA GM CCA ATT CAG GGT GAA GCA GGC G’lT Gil’ GTT 720 
Pro-Asp-Pro-Gly-Tyr-Leu-Met-Cly-V~l-ArS-Glu-Leu-Cy~-Thr-AirS-His-Gln-Val-Leu-Phe-Il~-Ala-~~lu-Ilc-Cla-fhr-Cly-L.u-Al~ 270 
CCG CAT CCA GGT TAC CTA ATG GGA GTG CGA GAG CTC TGC ACC AGG CAC CM: GlT CTC TTT ATT GCT CAT GAA ATA CAG ACA GGA TTG GCC 810 
CCC CAT CCA GGT TAC CTA ATG GGA GTC CGA GAG CTC TCC ACC At% CAC CAG GTT CTC Tl-l’ ATT GCT CAT GM ATA CAG ACA GGA TI’G CCC 810 
Arg-Thr-Gly-Arg-Trp-Leu-Ala-Val-Asp-Tyr-Glu-Aan-V~l-ArS-Pro-A~p-Ile-V~l-Leu-Leu-Gly-Ly~-Al~~~u-Ser~ly-Cly-Leu-Ty~-Pro 
AGA ACT GGT AGA TGG CTC GCT GTT CAT TAT GM MT GTC AGA CCT CAT ATA GTC CTC CTT GGA MC GCC Cl?' TCT GGG GGC l-711 TAC CCT 
ALGA ACT GGT AGA TGG CTG GCT GTT GAT TAT GAA MT GTC AGA CCT CAT ATA GTC CTC CTT GGA AAG GCC Cl-T CT GGG GGC TTA TAC CCT 
Val-Ser-Ala-VeI-Leu-Cys-Asp-A8p-Aep-Ila-i*t-Lcu-Thr-Il~-Ly8-Pro-Cly-Glu-~~~-Gly-S~r-Thr-Tyr-Gly-Cly-~n-Pr~~u-Gly-Cy~ 
GTC TCT GCA GTC CTG TGT CAT CAT GAC ATC ATG CTG ACC ATT MG CCA GGG GAG CAT GGG TCC ACA TAC GGT GGC MT CCA CTA GGC TGC 
GTG TCT GCA GTG CTG TGT GAT GAT GAC ATC ATG CTG ACC ATT MG CCL GGG GAG CAT GGG TCG ACA TAC GGT GGC MT CCA CTA GGC TGC 
ArS-Val-Ala-Ile-Ala-Ala-Leu-Glu-V~l-Lsu-Glu-G1u-Glu-A~n-Lsu-Ala-Glu-A~n-Al~-~p-Ly~-L~u~ly-I18-Il.-Leu-ArS-~n-Glu-L~u 
CCA GTG CCC ATC GCA GCC CTT GAG GTT TTA GM GM GAA MC Cll’ GCT CM MT GCA GAC MA TTC GGC ATT ATC TTG AGA MT GM CTC 
CGA GTC GCC ATC GCA CCC CTT GAG GTT TTA GM GM GM MC CTT GCT GM MT GCA GAC AAA TTG GGC ATT ATC TTG AGA MT GM CTC 
300 
900 
900 
330 
990 
990 
360 
1080 
1080 
H~r-Lys-Lau-Pro-Ser-Asp-Val-Val-Thr-Ala-Vel-Arg-Cly-Lys-Cly-Leu-Lcu-Aan-Als-Ile-V~1-Ile-Ly~-Glu-Thr-Lys-Asp-Trp-A~p-ALa 
ATG AAG CTA CCT TCT CAT GTT GTA ACT GCC GTA AGA GGA AM GGA TTA TTA MC GCT ATT GTC ATT AAA GA.4 ACC AM GAT TGG GAT GCT 
ATG AAG CTA CCT TCT CAT GTT GTA ACT CCC GTA AGA GGA AM GGA TTA TTA MC GCT ATT GTC ATT AAA GM ACC AAA CAT TGG GAT GCT 
390 
1170 
1170 
Trp-Lya-Vel-Cys-Leu-Arg-Leu-Arg-Asp-Asp-A~n-Gly-Leu-Leu-Al~-Ly8-Pro-Thr-H~~-Gly-A~p-Ilc-Il~-Arg-Phe-Al~-Pro-Pro-Leu-Val-Ile 420 
TGC AAC GTG TGT CTA CGA CTT CGA CAT MT GGA CTT CTG GCC MC CCA ACC CAT GGC GAC ATT ATC AGG TTT GCG CCT CCC CTG GTG ATC 1260 
TGG MG GTG TGT CTA CGA CT% CGA GAT MT GGA CTT CTG GCC MC CCA ACC CAT GGC GAC Al-i’ ATC AGG TTT GCG CCT CCG CTG GTG ATC 1260 
Lys-G1u-A~p-Gl.u-Lcu-ArS-Glu-Ser-Ile-Glu-Ile-Ile-Asn-Lys-Rtr-Ile-Lcu-Ser-Ph~ a** *** 
AAC GAG tiAT GAG CTT CGA GAG TCC ATT GAA ATT ATT MC MC ACC ATC TTG TCT l-l% T~TA~C~GT~TCC~~~~~TG 
AAG GAG GAT GAG CTT CGA GAG TCC ATT GM ATT ATT MC MC ACC ATC TTG TCT TTC TGA@%TAGCCAGCTGTTTTCA GTGGTCCCTGGGAGCCAGCTG 
GACACAGCTCGTCCTGTAAMG~A~C~MTGT~~~~CCACTCCCATGA~~C~C~~~TA TTTTTTTCAGTTGATACATMTAGMCAACGTT 
GAGAcAGGTU;TCCTGT~~T~A~C~MTGTGGGCA TTTWl'TcAG'lTGATAcATMT~GIT 
TATGMCCTGCCGmGC~GfMC~MCTMTOGCAT 
TATGMCCTCCCGTTTGCTTGTMCGTMCT~TMTGTMT~~TCTATATTCA~GMGTG~~GATGTGCATGTGTAC~CCTM~~~T~ATCTATATACAGACAG 
CCTCT~TC~GTCCTTCAGTATMTTGATATATG~ATM~CCTCACT~TATMGTG~CATATTTG~G~ATCTCT~TA~GCAT~~C~CATCTTATA 
AAGTGAAATCATTGn'ATTGMTTTTAGGMGCATTMTCGlA 
~"TTCAATTMCAATTAGCG~~CA~C~AM~G~GAGT~~GA~ATM~GT~TGTTTA~T~TAC~CTTT~TTT~T~~TTATAGTTT~ 
139 
1360 
1360 
1479 
lb79 
1553 
15Y8 
1717 
1836 
1955 
IY7l 
Fig.2. Nucleotide and amino acid sequence of human kidney OAT cDNA. The sequence of the 1587-nucleotide-long cDNA insert in 
the 1.5 kbp hkOAT-cDNA and 1.1 kbp hkQAT-cDNA is presented, as is the amino acid sequence, which is deduced from the open 
reading frame. The ammo acids are numbered starting with the initiating methionine as amino acid number 1. The putative cleavage 
site between the leader peptide and the purified mature hkOAT is shown by vertical dashes. Terminator codons are indicated by ***. 
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Ala-25. These differences in the site of cleavage of 
the OAT precursor may depend on the various dif- 
ferent preparations or on the secondary pro- 
cessing. 
3.3. Pyridoxal phosphate and L-ornithine binding 
site 
Fig.3. Ouchterlony double diffusion pattern of kidney, liver 
and brain OAT. Center well contains human kidney OAT 
antibody (purified IgG). Outer wells contain liver (l), kidney (2) 
and brain (3) purified OAT antigens. The antibody was raised 
with purified human kidney OAT as previously reported [16]. 
Titani, K., personal communication). On the other 
hand, Inana et al. [7] have postulated that the 
leader peptide of human OAT was cleaved after 
Lys-32, based on the apparent molecular mass of 
the mature OAT protein. Mueckler and Pitot [8] 
and Simmaco et al. [12] have postulated that the 
rat OAT precursor was processed after Glu-34 or 
Pyridoxal phosphate is a coenzyme which is 
necessary for all aminotransferases, including 
aspartate aminotransferase (AAT), tyrosine 
aminotransferase (TAT), serine aminotransferase 
(SAT), and OAT. Tanase et al. [13] have proposed 
that the partial amino acid sequence Ser-X-X-Lys 
is a structural feature common to most of the 
known pyridoxal phosphate binding sites. Se- 
quences such as Ser-X-X-Lys are present in these 
aminotransferases and ornithine decarboxylase 
(ODC), which is another pyridoxal phosphate- 
requiring enzyme. However, OAT, SAT, and 
ODC exhibit the right side-left reverse profile, such 
as Lys-X-X-Ser (fig.4). Hickok et al. 1141 have sug- 
gested that there is a hydrophilic region in ODC 
for the binding of L-ornithine. Similarly, OAT and 
ornithine carbamoyltransferase [ 151, which bind 
substrate L-ornithine, also contain hydrophilic 
regions (amino acid residues 307-343 and 
239-282, respectively). Interestingly, these 
hydrophilic regions in OAT and ODC are flanked 
with a Lys-X-X-Ser sequence. These regions and 
the Ser-X-X-Lys or Lys-X-X-Ser sequences may 
play an important role in the catalytic function of 
these enzymes, such as the binding of pyridoxal 
phosphate or L-ornithine. 
human OAT 
rat 
human mAAT 
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Fig.4. Comparison of the amino acid sequence of a putative 
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